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This article is a commentary on the following: Microglial Cells Impact Gut Microbiota and Gut 
Pathology in Angiotensin II-Induced Hypertension 
 
The pathophysiological mechanisms of hypertension are complex and involve multiple interacting 
systems (cardiac, vascular, renal, endocrine, neural, and immune) functioning on a genetic background 
influenced by environmental factors (epigenetics and epistasis). The complexity was highlighted over 
70 years ago in the Mosaic Theory of hypertension by Irvine Page.1 More recently, this theory has been 
revisited by David Harrison where molecular and cellular processes, specifically oxidative stress and 
inflammation, have been identified as common key events underlying the perturbed systems of the 
Mosaic Theory of hypertension.2 In the brain, oxidative stress and inflammatory processes increase 
neuronal firing in the cardioregulatory centers (neuroinflammation) and stimulate sympathetic 
nervous system activity, leading to vascular dysfunction and renal sodium retention, processes that 
cause blood pressure elevation.3 The importance of neuroinflammation in the pathogenesis of 
hypertension is based on increased cerebral levels of inflammatory mediators and cytokines produced 
by neurons and microglial cells in experimental models of hypertension, processes driven by activation 
of the renin-angiotensin-aldosterone system and other prohypertensive factors such as salt. 
To add to the complexity and multisystem network of the Mosaic Theory of hypertension, emerging 
experimental evidence indicates that the gut microbiota plays an important role in blood pressure 
regulation and metabolism. This was first demonstrated in the 1980s when modification of bacterial 
flora with antibiotics in rats was associated with steroid-related hypertension.4 Many studies have 
now shown that short-chain fatty acids (SCFAs), which are end products of fermentation by the gut 
microbiota, modulate blood pressure in mice.5 SCFAs are absorbed into the bloodstream where they 
exert effects on target tissues, including vessels, kidney, heart, and brain. In mice exposed to an acute 
bolus of SCFAs, blood pressure decreased rapidly through effects mediated primarily via the G-
protein–coupled receptor, Gpr41, localized in endothelial cells.6 Alterations in SCFA receptors in the 
small intestine have also been associated with elevated blood pressure in experimental 
models.7 Further demonstrating a role for gut microbiota in cardiovascular disease, propionate, an 
SCFA, significantly attenuated cardiac hypertrophy, fibrosis, vascular dysfunction, and blood pressure 
elevation in models of hypertension and atherosclerosis.8 Using new research strategies including 
metagenomics, which provides high resolution and culture-independent sequencing of bacterial DNA, 
bioinformatics analysis for microbial identification and taxonomy, fecal transplantation approaches as 
well as antibiotic-induced microbial depletion in experimental models, have further supported the 
pathophysiological role of gut microbial dysbiosis in hypertension. In experimental models of 
hypertension, administration of gastrointestinal-cleansing antibiotics caused a transient reduction in 
blood pressure and fecal transfer from hypertensive rats to normotensive rats caused hypertension in 
the recipient animals.9 Antibiotics, especially tetracyclines, such as minocycline, reduced blood 
pressure in spontaneously hypertensive rats10 and in Ang II-induced hypertension.11 In a case report, 
an antibiotic cocktail (vancomycin, rifampin, and ciprofloxacin) given for postsurgical infection, 
significantly altered the gut microbiota and reduced blood pressure in a patient with resistant 
hypertension.12 Together, these studies strongly suggest that the intestinal microbiome influences 
pathophysiological processes that regulate blood pressure. 
Specific mechanisms triggering gut dysbiosis–induced hypertension are unclear, but the gut enteric 
nervous system and extrinsic and central neural inputs seem to be important.13 This notion of neural-
gut communication was further developed by the Raizada group14 and more recently was found to be 
driven by the brain and sympathetic nerves and accordingly has been termed the brain-gut axis in 
hypertension as highlighted in the current issue.15 A comprehensive transcriptomic biomarker analysis 
in experimental hypertensive models using the Comparative Toxicogenomics Database demonstrated 
that transcriptomic data in the rodent central nervous system converge on processes associated with 
gastrointestinal function (transit, motility, and inflammation) supporting interplay between the brain 
and gut in neurogenic hypertension.16 However, the central elements driving the system remain 
elusive. 
In the current issue, Sharma et al15 provide new insights on how the central nervous system influences 
hypertension through the gastrointestinal system. In particular, they develop the theory that 
prohypertensive factors, especially Ang II, enhance sympathetic outflow and neuroinflammation 
through microglial activation, leading to sympathetic activation of the gut, altered gut microbiota, and 
increased mucosal permeability, processes promoting release of microbial toxins, proinflammatory 
mediators, and SCFAs into the circulation to cause systemic inflammation and blood pressure 
elevation. The concept of the leaky gut characterized by an increase in permeability of the 
gastrointestinal mucosa allowing bacterial toxins, metabolites, reactive oxygen species, 
proinflammatory molecules, and cytokines to leak into the bloodstream was originally associated with 
celiac disease and other inflammatory bowel diseases.17 However, as evidenced in the study in this 
issue,15 these processes are more widespread causing systemic inflammation implicated in a multitude 
of diseases including diabetes mellitus, chronic kidney disease, aneurysms, stroke, and 
hypertension.15,18The novelty of the Sharma study is that it clearly identifies microglial activation in 
the paraventricular nuclear region of the hypothalamus and neuroinflammation as being key drivers 
for the brain-gut axis in hypertension pathophysiology.15These findings were based on elegant 
experiments that investigated central effects of a chemically modified tetracycline-3 (CMT-3), which 
has primarily anti-inflammatory rather than antibiotic actions, on microglia activity, gut microbial 
communities and gut pathology, and blood pressure in hypertensive rats. CMT-3 administered 
intracerebroventricularly, but not peripherally, inhibited microglial activation, modified gut 
microbiota, improved gut integrity and reduced blood pressure, clearly defining a neuroinflammation-
gut link. This brain-gut communication is not unidirectional but appears to be bidirectional since gut 
microbiota and their products are also implicated in sympathetic nerve activity. Bacterial SCFAs have 
been shown to influence microglia homeostasis and neural control mechanisms in hypertension. 
Accordingly, the communication between the brain and the gut is circuitous where prohypertensive 
factors stimulate brain-gut communication and a leaky gut causing hypertension through systemic 
inflammatory processes and oxidative stress, which in turn promote sympathetic nervous system 
activation and perpetuation of the damaging processes underlying hypertension (Figure 1). 
 Figure 1 - Schematic demonstrating the circuitous relationship between prohypertensive factors, microglial activation, 
sympathetic outflow, and gut microbiota in the pathophysiology of hypertension. Neurogenic inflammation and oxidative 
stress are key molecular processes driving the brain-gut axis. Ang indicates angiotensin; PVN, paraventricular nucleus; and 
SNS, sympathetic nervous system. 
 
Targeting the dysfunctional brain-gut connection with antibiotics that have anti-inflammatory 
properties, such as CMT-3, may be a novel approach in the management of hypertension. However, 
there are a number of concerns and limitations that need to be addressed when such strategies are 
considered. First, antibiotics, and especially tetracyclines such as minocycline, have been associated 
with severe intracranial hypertension in both pediatric and adult patients.19,20 Hence, antibiotics may 
actually increase rather than decrease blood pressure, a phenomenon also observed in salt-sensitive 
hypertensive rats.10 Second, although CMT-3 was described as an anti-inflammatory tetracycline 
derivative in the article in this issue,15 it does have some antibiotic and antifungal actions and 
therefore the changes observed in the CMT-3–treated rats may not only be because of reduced 
neuroinflammation. Third, if antibiotics are indeed effective antihypertensive agents, acting in part 
through modulation of the gut microbiota, epidemiological, and clinical studies would have already 
shown a relationship between antibiotic use and blood pressure, especially considering the large 
population of patients who are hypertensive and on antibiotics for unrelated diseases. Finally, while 
research on experimental models has defined cross-talk between the brain and microbiota/gut in the 
pathophysiology of hypertension, evidence for such a system in humans still awaits confirmation. 
Nevertheless, based on preclinical data and from a theoretical viewpoint, the brain-gut axis in 
hypertension is certainly conceivable and could constitute a new axis to the framework of the Mosaic 
Theory of hypertension. However, to date, robust clinical evidence for this is still lacking. Before any 
consideration can be given for microglia-microbiota-gut targeted therapies to treat hypertension, 
unambiguous proof of clinical efficacy and safety without unwanted secondary effects is needed. 
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